PDT Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

PDT Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-151,956	Closed	-$804K	–	952
2021 Q2	$804K	Buy	+151,956	New	+$731K	0.05%	411
2021 Q1	–	Sell	-17,927	Closed	-$59K	–	913
2020 Q4	$59K	Buy	+17,927	New	+$68.1K	﹤0.01%	669
2020 Q3	–	Sell	-19,692	Closed	-$66K	–	893
2020 Q2	$66K	Buy	+19,692	New	+$93.1K	﹤0.01%	643
2019 Q2	–	Sell	-87,800	Closed	-$476K	–	480
2019 Q1	$476K	Buy	87,800 +34,400	+64%	+$167K	0.03%	320
2018 Q4	$159K	Buy	+53,400	New	+$292K	0.01%	421

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

PDT Partners's ZYNE Position: Q3 2021 in Review

PDT Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2021, closing a stake of 151,956 shares — an estimated $804K sold.

PDT Partners first reported a position in ZYNE in Q4 2018 and held it in 5 quarters. The position peaked at $804K in Q2 2021. 58 funds tracked by Wall St. Rank hold ZYNE as of Q3 2021.

PDT Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2021 after selling out during the quarter.
PDT Partners sold 151,956 Zynerba Pharmaceuticals, Inc shares in Q3 2021, an estimated $804K.
PDT Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2018 and held it in 5 quarters.
PDT Partners's Zynerba Pharmaceuticals, Inc position peaked at $804K in Q2 2021.
58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.